Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. - Wikidata - wikimedia - TriplyDB

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

http://www.wikidata.org/entity/Q33898182

about

New therapeutic strategies for BRAF mutant colorectal cancers ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma New developments in the management of advanced melanoma - role of pembrolizumab Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Universes collide: combining immunotherapy with targeted therapy for cancer Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy EZH2 as a mediator of treatment resistance in melanoma Emerging clinical applications of selected biomarkers in melanoma Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Clinical and biological determinants of melanoma progression: Should all be considered for clinical management?CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.Vemurafenib and ipilimumab: A promising combination? Results of a case series Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Advances in immunotherapy for melanoma management.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.Crosstalk signaling in targeted melanoma therapy.Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.Principles of Kinase Inhibitor Therapy for Solid Tumors.Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

P2860

Q26772277-A5D5D54B-A7F3-4DB7-897B-74FECFC76CBE Q26777288-4F375F55-DE05-4028-8749-A5F81C121749 Q26781931-813A9B2B-8B0E-4843-A421-C4E7225506C0 Q26796309-ABDDF6AE-4B9C-409A-B5BE-E8672C28CD78 Q26825316-B8C11644-3CCE-4E5A-8CA1-450D55126E7D Q28066199-5D0B9EE3-A646-4B0D-A73C-5D28773B4ABE Q28074492-FCDE2313-9598-443D-AC48-76C66278964C Q28087169-42834685-69B7-4106-9B15-163058200BD1 Q29994573-996CD8FC-5AE5-4872-9547-71F5009659FE Q30252150-EDD4EDB7-0370-46BB-A261-F634198DAA7B Q33902560-52315E22-31FE-40BB-B0A0-55FE904C9886 Q34667825-124A86E1-0037-4F75-9799-A8E9BC56C4FA Q34786402-C8CD6958-BD82-4393-AE64-F7BAF532B1FF Q34892977-4791DB41-B01C-478A-9C46-A74C61CD5A43 Q35156866-DF3F59D7-0046-4D92-A708-19AF6CED8AA0 Q35862663-A8BFA39F-076A-4ABC-8877-D2413FFE1814 Q35987305-ABBD52F6-5617-43A4-999C-5AA9A6392B28 Q36222122-0D99EEC2-1292-4711-8259-50DFC67849FA Q36553576-820EAB32-DEBE-4F8A-B1C4-E0B38D6C87F2 Q36612452-701E7CE9-323B-468B-B5B2-B498B941A71E Q36759429-5489EE84-93ED-4AA5-87C7-4098C33F634A Q36821040-7F9127A1-A3EA-455D-9F73-5C15AA8C5CDE Q36821164-E223B009-B281-41EE-995C-B3A03AB253ED Q36821239-26AB4A86-B2E9-4327-BE7C-668840431F49 Q37066925-D9AFD135-8E04-481F-89E7-CEE620029061 Q37086237-155F7458-5BC8-450B-B9D3-4A4DE7D67195 Q37375978-F510E2B4-62BA-46AA-BAB5-FC19B460A725 Q37417271-0B049E88-A177-4C89-8FFC-B13CC0C696F2 Q38327993-A5A55616-9FA7-4D85-985F-C973424008D3 Q38553161-5DFC9DEC-455E-491D-B3C0-8AC980E2C6D6 Q38619615-4DED69DD-4F90-4FD0-94BB-5EDBF97104C0 Q38711929-DC2E91A1-0C13-4BDC-9437-7F51A02E3B98 Q38716324-62E2EEB4-00CF-415B-A861-D4AB96869A8D Q38757522-3B831FCC-9961-484F-9D96-9C3B6FABABF7 Q38759531-76BE52FF-CFBF-4AB7-ADA7-56488E81CC1F Q38776860-BD224A73-23A0-41AA-A564-2555C0EDF5F5 Q38802154-CC29BA15-D0E0-4AEE-8BA2-1BBE382E0DF1 Q38813507-D84FDEBB-B88E-46DB-93F0-3404B189F9AD Q38842141-EE8AAAF2-0C5A-4CEC-B79C-CA927CC1ECDE Q38998443-050C2E78-D9E3-4B53-BB63-28E04F26184B

P2860

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

http://www.wikidata.org/entity/Q33898182

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@ast

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@en

type

label

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@ast

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@en

prefLabel

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@ast

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@en

P1433

Q33898182-F2983D68-1E6E-4376-9B74-8ED397C40F3C

P1476

Q33898182-B912526C-71CD-4861-BF51-70C78C24F27E

P2093

Q33898182-1D027E86-C9A4-4B3E-BDB8-D49B4D7C3B0D

Q33898182-23F7DE38-F035-47C4-A8DF-5805CC758573

Q33898182-401A5DE6-69AD-461D-ABCD-FBBE649A921E

Q33898182-5E3545F7-C393-46C6-AA3C-4C45CCF7C43D

Q33898182-72F5B603-E211-4C0D-8B69-2160EC43B981

Q33898182-73478702-3F72-457A-A860-3CB35ABD8824

Q33898182-8BAA49DC-1B32-408F-A72B-C660B676A478

Q33898182-9CC2123B-65FF-4731-A3B1-D8467AF47FE9

Q33898182-BEB487A1-9837-406F-B2EA-ACDC0680FB3E

Q33898182-C179ABD4-1581-4D2C-8B7C-D9240D52A07F

P2860

Q33898182-0C02C411-EE84-4ABA-9128-4971E6132A76

Q33898182-125AF787-9FDD-4C17-9838-676FF0AD5772

Q33898182-19BF094C-6241-4F80-B936-6048569DFB58

Q33898182-2BBC75AB-4A47-4888-8D33-2914E8A38440

Q33898182-31DA282B-68F0-4C94-BA73-8DD02FCDB9A9

Q33898182-3641193F-2672-473F-BB74-78F48C8B053B

Q33898182-38E2F47F-2715-49FA-B9A9-1A5F311C3087

Q33898182-3BD358A8-FCCC-4C1F-B07E-2E722D1F4037

Q33898182-3C313DC4-F2F0-4CAC-916B-97726117366E

Q33898182-3C810C2B-0A9C-412B-833D-989B71B728E5

P304

Q33898182-41CDF778-D548-4AD4-A9A9-4E2DD9F3B465

P31

Q33898182-FEE42464-15C3-426F-950C-5B7E23593E0F

P356

Q33898182-B6905469-2D72-49A3-A75E-3232B0A9CA3C

P433

Q33898182-0EBD4391-E2E4-4792-8825-4B9A691F9053

P478

Q33898182-91ADD010-A76C-4107-8935-FDCB209BEBD0

P50

Q33898182-0000039A-F90C-4A7B-987D-F905F961FB26

Q33898182-05258215-B44C-40C8-A132-8815CB38BDAF

Q33898182-A45A7A93-52A9-4262-8982-17908C8B63EA

P577

Q33898182-F09E9C55-63A7-4481-9C1D-E1BC5538D5E4

P698

Q33898182-347CACC2-9F6D-4F73-A037-40091F1B24A3

P932

Q33898182-63A2FBD7-B852-487F-B7B4-3FD5B4673612

P356

2326-6066.CIR-13-0215

P1433

Cancer immunology research

P1476

Response to BRAF inhibition in ...... th immune checkpoint blockade.

@en

P2093

Adriano Piris

http://www.w3.org/2001/XMLSchema#string

David E Fisher

http://www.w3.org/2001/XMLSchema#string

Dennie T Frederick

http://www.w3.org/2001/XMLSchema#string

Devarati Mitra

http://www.w3.org/2001/XMLSchema#string

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Gordon J Freeman

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Keith T Flaherty

http://www.w3.org/2001/XMLSchema#string

Marcus W Bosenberg

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

PD-1 and its ligands in tolerance and immunity

P304

643-654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0215

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Zachary A. Cooper

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24903021

http://www.w3.org/2001/XMLSchema#string

P932

4097121

http://www.w3.org/2001/XMLSchema#string